FDA Accepts Supplement for SAXENDA (Liraglutide) by Novo
The FDA has accepted a supplemental application for SAXENDA, an obesity treatment containing liraglutide.
Asset / Drug
Drug and asset intelligence for SAXENDA with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
GLP-1 Agonist
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.